Enhancement of antinociception by coadministration of nonsteroidal anti-inflammatory drugs and soluble epoxide hydrolase inhibitors

Kara R. Schmelzer, Bora Inceoglu, Lukas Kubala, In Hae Kim, Steven L. Jinks, Jason P. Eiserich, Bruce D. Hammock

Research output: Contribution to journalArticle

128 Citations (Scopus)

Abstract

Combination therapies have long been used to treat inflammation while reducing side effects. The present study was designed to evaluate the therapeutic potential of combination treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) and previously undescribed soluble epoxide hydrolase inhibitors (sEHIs) in lipopolysaccharide (LPS)-challenged mice. NSAIDs inhibit cyclooxygenase (COX) enzymes and thereby decrease production of metabolites that lead to pain and inflammation. The sEHIs, such as 12-(3-adamantan-1-yl-ureido)-dodecanoic acid butyl ester (AUDA-BE), stabilize anti-inflammatory epoxy-eicosatrienoic acids, which indirectly reduce the expression of COX-2 protein. Here we demonstrate that the combination therapy of NSAIDs and sEHIs produces significantly beneficial effects that are additive for alleviating pain and enhanced effects in reducing COX-2 protein expression and shifting oxylipin metabolomic profiles. When administered alone. AUDA-BE decreased protein expression of COX-2 to 73 ± 6% of control mice treated with LPS only without altering COX-1 expression and decreased PGE2 levels to 52 ± 8% compared with LPS-treated mice not receiving any therapeutic intervention. When AUDA-BE was used in combination with low doses of indomethacin, celecoxib, or rofecoxib, PGE2 concentrations dropped to 51 ± 7, 84 ± 9, and 91 ± 8%, respectively, versus LPS control, without disrupting prostacyclin and thromboxane levels. These data suggest that these drug combinations (NSAIDs and sEHIs) produce a valuable beneficial analgesic and anti-inflammatory effect while prospectively decreasing side effects such as cardiovascular toxicity.

Original languageEnglish (US)
Pages (from-to)13646-13651
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume103
Issue number37
DOIs
StatePublished - Sep 12 2006

Fingerprint

Epoxide Hydrolases
lauric acid
Anti-Inflammatory Agents
Lipopolysaccharides
Cyclooxygenase 2
Esters
Pharmaceutical Preparations
Celecoxib
Dinoprostone
Oxylipins
Inflammation
Therapeutics
Pain
Cyclooxygenase 1
Proteins
Metabolomics
Thromboxanes
Non-Steroidal Anti-Inflammatory Agents
Epoprostenol
Drug Combinations

Keywords

  • Arachidonic acid
  • Cyclooxygenase
  • Epoxygenase
  • Linoleic acid
  • Pain

ASJC Scopus subject areas

  • Genetics
  • General

Cite this

Enhancement of antinociception by coadministration of nonsteroidal anti-inflammatory drugs and soluble epoxide hydrolase inhibitors. / Schmelzer, Kara R.; Inceoglu, Bora; Kubala, Lukas; Kim, In Hae; Jinks, Steven L.; Eiserich, Jason P.; Hammock, Bruce D.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 103, No. 37, 12.09.2006, p. 13646-13651.

Research output: Contribution to journalArticle

Schmelzer, Kara R. ; Inceoglu, Bora ; Kubala, Lukas ; Kim, In Hae ; Jinks, Steven L. ; Eiserich, Jason P. ; Hammock, Bruce D. / Enhancement of antinociception by coadministration of nonsteroidal anti-inflammatory drugs and soluble epoxide hydrolase inhibitors. In: Proceedings of the National Academy of Sciences of the United States of America. 2006 ; Vol. 103, No. 37. pp. 13646-13651.
@article{757a3cd8992a4d3b903c9203d47bf4bb,
title = "Enhancement of antinociception by coadministration of nonsteroidal anti-inflammatory drugs and soluble epoxide hydrolase inhibitors",
abstract = "Combination therapies have long been used to treat inflammation while reducing side effects. The present study was designed to evaluate the therapeutic potential of combination treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) and previously undescribed soluble epoxide hydrolase inhibitors (sEHIs) in lipopolysaccharide (LPS)-challenged mice. NSAIDs inhibit cyclooxygenase (COX) enzymes and thereby decrease production of metabolites that lead to pain and inflammation. The sEHIs, such as 12-(3-adamantan-1-yl-ureido)-dodecanoic acid butyl ester (AUDA-BE), stabilize anti-inflammatory epoxy-eicosatrienoic acids, which indirectly reduce the expression of COX-2 protein. Here we demonstrate that the combination therapy of NSAIDs and sEHIs produces significantly beneficial effects that are additive for alleviating pain and enhanced effects in reducing COX-2 protein expression and shifting oxylipin metabolomic profiles. When administered alone. AUDA-BE decreased protein expression of COX-2 to 73 ± 6{\%} of control mice treated with LPS only without altering COX-1 expression and decreased PGE2 levels to 52 ± 8{\%} compared with LPS-treated mice not receiving any therapeutic intervention. When AUDA-BE was used in combination with low doses of indomethacin, celecoxib, or rofecoxib, PGE2 concentrations dropped to 51 ± 7, 84 ± 9, and 91 ± 8{\%}, respectively, versus LPS control, without disrupting prostacyclin and thromboxane levels. These data suggest that these drug combinations (NSAIDs and sEHIs) produce a valuable beneficial analgesic and anti-inflammatory effect while prospectively decreasing side effects such as cardiovascular toxicity.",
keywords = "Arachidonic acid, Cyclooxygenase, Epoxygenase, Linoleic acid, Pain",
author = "Schmelzer, {Kara R.} and Bora Inceoglu and Lukas Kubala and Kim, {In Hae} and Jinks, {Steven L.} and Eiserich, {Jason P.} and Hammock, {Bruce D.}",
year = "2006",
month = "9",
day = "12",
doi = "10.1073/pnas.0605908103",
language = "English (US)",
volume = "103",
pages = "13646--13651",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "37",

}

TY - JOUR

T1 - Enhancement of antinociception by coadministration of nonsteroidal anti-inflammatory drugs and soluble epoxide hydrolase inhibitors

AU - Schmelzer, Kara R.

AU - Inceoglu, Bora

AU - Kubala, Lukas

AU - Kim, In Hae

AU - Jinks, Steven L.

AU - Eiserich, Jason P.

AU - Hammock, Bruce D.

PY - 2006/9/12

Y1 - 2006/9/12

N2 - Combination therapies have long been used to treat inflammation while reducing side effects. The present study was designed to evaluate the therapeutic potential of combination treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) and previously undescribed soluble epoxide hydrolase inhibitors (sEHIs) in lipopolysaccharide (LPS)-challenged mice. NSAIDs inhibit cyclooxygenase (COX) enzymes and thereby decrease production of metabolites that lead to pain and inflammation. The sEHIs, such as 12-(3-adamantan-1-yl-ureido)-dodecanoic acid butyl ester (AUDA-BE), stabilize anti-inflammatory epoxy-eicosatrienoic acids, which indirectly reduce the expression of COX-2 protein. Here we demonstrate that the combination therapy of NSAIDs and sEHIs produces significantly beneficial effects that are additive for alleviating pain and enhanced effects in reducing COX-2 protein expression and shifting oxylipin metabolomic profiles. When administered alone. AUDA-BE decreased protein expression of COX-2 to 73 ± 6% of control mice treated with LPS only without altering COX-1 expression and decreased PGE2 levels to 52 ± 8% compared with LPS-treated mice not receiving any therapeutic intervention. When AUDA-BE was used in combination with low doses of indomethacin, celecoxib, or rofecoxib, PGE2 concentrations dropped to 51 ± 7, 84 ± 9, and 91 ± 8%, respectively, versus LPS control, without disrupting prostacyclin and thromboxane levels. These data suggest that these drug combinations (NSAIDs and sEHIs) produce a valuable beneficial analgesic and anti-inflammatory effect while prospectively decreasing side effects such as cardiovascular toxicity.

AB - Combination therapies have long been used to treat inflammation while reducing side effects. The present study was designed to evaluate the therapeutic potential of combination treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) and previously undescribed soluble epoxide hydrolase inhibitors (sEHIs) in lipopolysaccharide (LPS)-challenged mice. NSAIDs inhibit cyclooxygenase (COX) enzymes and thereby decrease production of metabolites that lead to pain and inflammation. The sEHIs, such as 12-(3-adamantan-1-yl-ureido)-dodecanoic acid butyl ester (AUDA-BE), stabilize anti-inflammatory epoxy-eicosatrienoic acids, which indirectly reduce the expression of COX-2 protein. Here we demonstrate that the combination therapy of NSAIDs and sEHIs produces significantly beneficial effects that are additive for alleviating pain and enhanced effects in reducing COX-2 protein expression and shifting oxylipin metabolomic profiles. When administered alone. AUDA-BE decreased protein expression of COX-2 to 73 ± 6% of control mice treated with LPS only without altering COX-1 expression and decreased PGE2 levels to 52 ± 8% compared with LPS-treated mice not receiving any therapeutic intervention. When AUDA-BE was used in combination with low doses of indomethacin, celecoxib, or rofecoxib, PGE2 concentrations dropped to 51 ± 7, 84 ± 9, and 91 ± 8%, respectively, versus LPS control, without disrupting prostacyclin and thromboxane levels. These data suggest that these drug combinations (NSAIDs and sEHIs) produce a valuable beneficial analgesic and anti-inflammatory effect while prospectively decreasing side effects such as cardiovascular toxicity.

KW - Arachidonic acid

KW - Cyclooxygenase

KW - Epoxygenase

KW - Linoleic acid

KW - Pain

UR - http://www.scopus.com/inward/record.url?scp=33748797975&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748797975&partnerID=8YFLogxK

U2 - 10.1073/pnas.0605908103

DO - 10.1073/pnas.0605908103

M3 - Article

C2 - 16950874

AN - SCOPUS:33748797975

VL - 103

SP - 13646

EP - 13651

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 37

ER -